Acute Pain Drug Pipeline Analysis Report 2025

According to the National Institutes of Health’s National Center for Complementary and Integrative Health (NCCIH), approximately 40 million adults (17.6%) people experience severe levels of pain in the United States. The treatment for acute pain includes drugs and therapies. Common drugs include anti-seizure drugs, shots, muscle relaxers, and opioids. Several clinical trials are developing acute pain therapeutics including analgesics. The FDA has recently granted VX-548 Breakthrough Therapy Designation for the treatment of moderate to severe acute pain.

Report Coverage

The Acute Pain Drug Pipeline Report by the publisher gives comprehensive insights into acute pain drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for acute pain. The acute pain pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from acute pain.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing acute pain pipeline development activities are covered in the report.

Acute Pain Drug Pipeline Outlook

Acute pain comes on suddenly and is caused by something specific usually and it is sharp in quality. This pain usually doesn’t last longer than a period of six months. It may be related to soft-tissue injury also or sometimes a temporary illness. The pain from an injury develops into chronic pain if the injury doesn’t heal correctly. The causes of acute pain include surgery, broken bones, burns or cuts, labor, and childbirth among others. The symptoms of acute pain include burning, numbness, tingling, and weakness among others.

Acute pain therapeutic drugs include medications, massage therapy, physical therapy, and topical treatments among others. The medications include anti-seizure drugs, shots, muscle relaxers, and opioids. Anti-seizure drugs relieve numbness and tingling (if there is nerve damage). Sometimes doctors prescribe injecting a corticosteroid medicine in the injured areas to reduce inflammation. Muscle relaxers help loosen tight muscles and opioids are prescribed drugs to relieve severe acute pain. Several pharma companies and research institutes are developing acute pain emerging drugs to manage acute pain. For instance, analgesic trials are investigated for acute pain in the context of traumatic injury or surgical procedures. The increasing clinical trials and changing dynamics are impacting the acute pain clinical trial landscape significantly.

Acute Pain - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of acute pain drugs based on several segmentations including:

By Phase:

The pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class:

The acute pain therapeutic assessment covers 50+ drug analyses based on drug classes:

• Oligonucleotide
• Peptide
• Small Molecule

By Route of Administration:

The acute pain clinical assessment covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Acute Pain - Pipeline Assessment Segmentation, By Phases

The acute pain report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase IV covers a major share of the total clinical trials for acute pain.

Acute Pain - Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under acute pain pipeline analysis include oligonucleotide, peptide, and small molecule. Small molecules are used to develop acute pain treatment such as nociceptor-selective treatments. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for acute pain.

Acute Pain Clinical Trials Assessment - Competitive Dynamics

The acute pain report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in acute pain clinical trials:

• Centrexion Therapeutics
• Alaxia SAS
• Purdue Pharma, Canada
• Aponia Laboratories, Inc.
• Mundipharma SAS
• Apsen Farmaceutica S.A.
• Trevena Inc.
• Tris Pharma, Inc.
• Vertex Pharmaceuticals Incorporated
• Pharmbio Korea Co., Ltd.
• Unither Pharmaceuticals, France
• Sparian Biosciences, Inc
• Others

Acute Pain - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and acute pain therapeutic drugs. It covers necessary details such as product description, study type, drug class, mode of administration, and recruitment status of upcoming acute pain drug candidates.

Drug: Etodolac

The trial is designed to compare the efficacy of the fixed-dose combination of etodolac and cyclobenzaprine in postoperative pain control. The trial is sponsored by Apsen Farmaceutica S.A. and is currently under phase III.

Drug: VX-548

The objective of the study is to assess the safety and efficacy of acute pain drug candidate VX-548 for treating acute pain after an abdominoplasty. The trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently under phase III.

Drug: VX-150

Vertex Pharmaceuticals Incorporated is developing the drug and is currently under phase II. The study is being conducted to assess the dose-response relationship and safety of VX-150 in treating acute pain.

Reasons To Buy This Report

The Acute Pain Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for acute pain. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within acute pain pipeline insight.

Key Questions Answered in the Acute Pain - Pipeline Assessment Report

• What is the current landscape of acute pain disease pipeline drugs?
• Which companies/institutions are developing acute pain disease emerging drugs?
• How many phase II drugs are currently present in acute pain disease pipeline drugs?
• Which company is leading the acute pain disease pipeline development activities?
• What is the current acute pain disease therapeutic assessment?
• What are the opportunities and challenges present in the acute pain disease drug pipeline landscape?
• What is the efficacy and safety profile of acute pain disease pipeline drugs?
• Which companies/institutions are involved in acute pain disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in acute pain disease?

This product will be delivered within 3-5 business days.